NCT02049606已完成4 期
Double Blinded, Randomized, Active Drug Comparative, Multi-center, Phase Ⅳ Clinical Study to Compare the Efficacy and Safety of LAYLA in Osteoarthritis Patients of the Knee.
PMG Pharm Co., Ltd6 个研究点 分布在 1 个国家目标入组 134 人开始时间: 2014年2月24日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 134
- 试验地点
- 6
- 主要终点
- Changes from the baseline in 100mm Pain VAS
研究概览
简要总结
This is a randomized, double-blind study to compare the efficacy and safety of LAYLA tablet and CENATONE tablet in the treatment of osteoarthritis of the knee.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 40 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients ≥40 and ≤80 years of age
- •Radiographic evidence of grade 1,2 or 3 osteoarthritis based on the Kellgren & Lawrence radiographic entry criteria
- •Stable osteoarthritis during 3 months
- •Score of 100mm Pain VAS ≤ 80mm at screening
- •Score of 100mm Pain VAS ≥ 40mm at baseline
- •Written consent form voluntarily
排除标准
- •Disease of spine or other Lower limb joints that could affect fo evaluate the efficacy
- •History of surgery or arthroscopy of the study joint within 6 months
- •Trauma of study joint within 12 months
- •Medication of constantly(more than 1 week) corticosteroid by oral within 3 months
- •Diagnosed with psychical disorder, and taking medication
- •Medication of intra-articular injection within 3 months
- •Uncontrollable Hypertension patients at screening test
- •History of upper gastrointestinal ulceration within 6 months, History of upper gastrointestinal bleeding within 12 months
- •History of lower gastrointestinal bleeding within 12 months
- •History of coronary artery bypass, systemic lupus erythematosus or mixed connective tissue disease
- •Serum creatinine, ALT, AST, total bilirubin over ULN X 2.0 at screening test
- •History of hypersensitivity of LAYLA, CENATONE or NSAIDs
- •Participation in another clinical trials within 4 weeks
- •Medication of constantly (more than 1 week) narcotic analgesics within 3 months
- •Not consent about using effectual contraception method during trial
- •Pregnant or lactating woman
- •History of malignant tumor within 5 years
- •Investigator's judgment
研究组 & 干预措施
CENATONE
Active Comparator
Drug : CENATONE tablet/qd
干预措施: CENATONE tablet (Drug)
LAYLA
Experimental
Drug : LAYLA tablet/bid
干预措施: LAYLA tablet (Drug)
结局指标
主要结局
Changes from the baseline in 100mm Pain VAS
时间窗: Baseline through week8
次要结局
- Changes rate from the baseline in 100mm Pain VAS(8 weeks)
- Changes from the baseline in EQ-5D(8 Weeks)
- Changes in the patient self-assessed overall symptom score(8 Weeks)
- Changes from the baseline in WOMAC(8 Weeks)
研究者
研究点 (6)
Loading locations...
相似试验
已完成
4 期
To Compare the Efficacy and Safety of LAYLA in Osteoarthritis PatientsOsteoarthritis of the KneeNCT01768468PMG Pharm Co., Ltd124
已完成
1 期
Comparative Study of Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of Single Intravenous Doses of BCD-148 and Soliris®Healthy SubjectsNCT04027803Biocad78
已完成
3 期
A Study of Two Approved Drugs in the Treatment of Post-Bunionectomy Surgery Pain (0966-234)(COMPLETED)Postoperative PainNCT00092378Merck Sharp & Dohme LLC251
已完成
3 期
A Study of Two Approved Drugs in the Treatment of Postoperative Dental Pain (0966-181)(COMPLETED)Postoperative PainNCT00092300Merck Sharp & Dohme LLC450
已完成
3 期
A Study of Two Approved Drugs in the Treatment of Postoperative Dental Pain (0966-182)Postoperative PainNCT00092313Merck Sharp & Dohme LLC271